On the 4th, Helios announced that it was effectively transferred from Athersys, Inc. (Ohio), an American biotechnology company that filed for Chapter 11 bankruptcy protection (equivalent to Japan's Civil Rehabilitation Act) in January of this year and went bankrupt. announced that it had completed the acquisition of all assets on April 3
Athersys is an Ohio-based biotechnology company that researches and develops stem cell therapeutics for the treatment of neurological and cardiovascular diseases.